Announcements
- Addex to Present at the Swiss Biotech Day 2024
- Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
- Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024
- Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
- Addex to Present at the Bio-Europe Spring 2024 Conference
- Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.
- Addex to Present at the Swiss Equities Baader Conference
- Addex to Present at Biotech Showcase™ 2024
- Addex Shareholders Approve All Resolutions at Extraordinary General Meeting
- Addex Creates Treasury Shares
More ▼
Key statistics
On Friday, Addex Therapeutics Ltd (APE1:FRA) closed at 20.00, -28.06% below its 52-week high of 27.80, set on Apr 11, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 0.00 |
Low | 0.00 |
Bid | 14.00 |
Offer | 15.80 |
Previous close | 20.00 |
Average volume | 450.00 |
---|---|
Shares outstanding | 1.54m |
Free float | 992.84k |
P/E (TTM) | -- |
Market cap | 23.35m USD |
EPS (TTM) | -209.27 USD |
Data delayed at least 15 minutes, as of Apr 19 2024 14:37 BST.
More ▼